E
Ernexa Therapeutics Inc. (ERNA)
NCM – Real Time Price. Currency in USD
12.01
+4.80 (66.57%)
At close: May 12, 2026, 4:00 PM EDT
12.56
+0.55 (4.58%)
Pre-market: May 13, 2026, 6:13 AM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
12.01
+4.80 (66.57%)
At close: May 12, 2026, 4:00 PM EDT
12.56
+0.55 (4.58%)
Pre-market: May 13, 2026, 6:13 AM EDT
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company’s lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
| Name | Position |
|---|---|
| Dr. Kanika Chawla Ph.D. | Senior Vice President of Technical Operations (Consultant) |
| Dr. Robert Hamilton Pierce M.D. | Chief Scientific Officer |
| Mr. Sanjeev Luther | CEO, President & Director |
| Ms. Dorothy J. Clarke | General Counsel |
| Ms. Sandra M. Gurrola | Senior VP of Finance |
| Date | Type | Document |
|---|---|---|
| 2026-05-04 | 8-K | form8-k.htm |
| 2026-04-13 | DEF 14C | formdef14c.htm |
| 2026-04-01 | PRE 14C | formpre14c.htm |
| 2026-03-26 | CORRESP | filename1.htm |
| 2026-03-24 | S-3/A | forms-3a.htm |
| 2026-03-20 | 8-K | form8-k.htm |
| 2026-03-16 | S-3 | forms-3.htm |
| 2026-03-13 | 10-K | form10-k.htm |
| 2026-02-26 | 8-K | form8-k.htm |
| 2026-02-11 | 8-K | form8-k.htm |